|
2014
Dec 31, 2013 17:00:46 GMT -5
Post by biotec on Dec 31, 2013 17:00:46 GMT -5
Well another year. I was at this time last year thinking 2013 was going to be the year for mannkind. Yes the stock went up but still very disappointed were we are at. Who thinks the same? I hope 2014 is a great year for us longs. One article this year keeps bugging me, I tried to look it up but couldn't find it today. It was this summer with a CEO from a BP ( I thought merck) They asked about mnkd and the answer was that mnkd is only a filler insulin and not a drug that they was looking at (Please if you find it, post it). Well happy new years. Lets hope 2014 does us longs justice. I hope to harvest some profits soon.
Bio
|
|
|
2014
Dec 31, 2013 19:20:55 GMT -5
Post by spiro on Dec 31, 2013 19:20:55 GMT -5
Bio,
It's just another dumb CEO, who is clueless about what Afrezza can do. He obviously knows little about Afrezza.
Happy New year to all,
Spiro
|
|
|
Post by brentie on Dec 31, 2013 23:46:45 GMT -5
Well another year. I was at this time last year thinking 2013 was going to be the year for mannkind. Yes the stock went up but still very disappointed were we are at. Who thinks the same? I hope 2014 is a great year for us longs. One article this year keeps bugging me, I tried to look it up but couldn't find it today. It was this summer with a CEO from a BP ( I thought merck) They asked about mnkd and the answer was that mnkd is only a filler insulin and not a drug that they was looking at (Please if you find it, post it). Well happy new years. Lets hope 2014 does us longs justice. I hope to harvest some profits soon. Bio Bio, is this what you are looking for? IBD: Would the launch of MannKind's Afrezza inhaled insulin product have an impact on your business? Brandgaard: We have been down the road of inhaled insulin, and we terminated our projects after Pfizer (PFE) had to conclude that their Exubera (inhaled insulin) product was not commercially successful. The challenge we see with Afrezza is that it is solely a product you use for mealtime. Typically, patients who need mealtime insulin will also need long-acting insulin. Since you then anyway have to inject yourself with the long-acting insulin, one could question how big the benefit is of being able to take your insulin by inhalation for the mealtime. So we're not intending to go down that route again. We think our approach of trying to make insulin in a tablet form could probably be more interesting, because where we see the injection as being the major hurdle is predominantly in Type 2. In Type 2 diabetes, the insulin the patients would need to start with would predominantly be a long-acting insulin. We see the inhalable insulin more as a specialist product. news.investors.com/091013-670467-novo-nordisk-stock-recovering-from-setbacks.htm?ven=yahoocp,yahoo&src=aurlled
|
|
|
Post by brentie on Dec 31, 2013 23:59:37 GMT -5
I detect a difference of opinion here... Brandgaard: "In Type 2 diabetes, the insulin the patients would need to start with would predominantly be a long-acting insulin. We see the inhalable insulin more as a specialist product." And then there's... Aren’t most Type 2s currently treated with a basal insulin only, instead of mealtime dosing? Al: Yes, but that’s the wrong way around. The correct therapy should be a good prandial insulin and not long-term insulin — Afresa in particular because it turns off glucose production and delivery from the liver. Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients. www.diabetesmine.com/2009/11/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann.html
|
|
|
2014
Jan 1, 2014 9:00:53 GMT -5
Post by biotec on Jan 1, 2014 9:00:53 GMT -5
IBD: Would the launch of MannKind's Afrezza inhaled insulin product have an impact on your business? Brandgaard: We have been down the road of inhaled insulin, and we terminated our projects after Pfizer (PFE) had to conclude that their Exubera (inhaled insulin) product was not commercially successful. The challenge we see with Afrezza is that it is solely a product you use for mealtime. Typically, patients who need mealtime insulin will also need long-acting insulin. Since you then anyway have to inject yourself with the long-acting insulin, one could question how big the benefit is of being able to take your insulin by inhalation for the mealtime. So we're not intending to go down that route again. We think our approach of trying to make insulin in a tablet form could probably be more interesting, because where we see the injection as being the major hurdle is predominantly in Type 2. In Type 2 diabetes, the insulin the patients would need to start with would predominantly be a long-acting insulin. We see the inhalable insulin more as a specialist product. Read More At Investor's Business Daily: news.investors.com/technology-tech-exec-qanda/091013-670467-novo-nordisk-stock-recovering-from-setbacks.htm#ixzz2p9gSMhiA Follow us: @ibdinvestors on Twitter | InvestorsBusinessDaily on Facebook I found it. From Sept. Interview with the CFO of novo nordisk.
|
|
|
Post by biotec on Jan 1, 2014 9:12:29 GMT -5
Yes brentie, Thanks. This is from the CFO of novo nordisk. This always buged me seeing novo is the king of insulin.
|
|
|
2014
Jan 1, 2014 13:48:01 GMT -5
Post by MnkdMainer (MM) on Jan 1, 2014 13:48:01 GMT -5
I detect a difference of opinion here... Brandgaard: "In Type 2 diabetes, the insulin the patients would need to start with would predominantly be a long-acting insulin. We see the inhalable insulin more as a specialist product." And then there's... Aren’t most Type 2s currently treated with a basal insulin only, instead of mealtime dosing? Al: Yes, but that’s the wrong way around. The correct therapy should be a good prandial insulin and not long-term insulin — Afresa in particular because it turns off glucose production and delivery from the liver. Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients. www.diabetesmine.com/2009/11/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann.htmlI would like to see Brandgaard respond to Al's assertion.
|
|
|
Post by jpg on Jan 1, 2014 18:47:24 GMT -5
I think the science backs Mann on this debate. A well run large and long lasting trial in type 2 patients would be necessary to scientifically 'seal the deal' though.
Medicine, like any other field, tends to find solutions with the available tools then, when new better tools become available, changes treatment paradigms. This is what I think will happen with Affrezza. The Novo Noridisk CEO is just trying to protect the status quo since his company makes the best available tools for treating diabetes pre Afrezza. His above comments will also be the 'pitch' his reps make to MDs when Affrezza is approved unless obviously Novo Nordisk is the partner (which I hope it isn't: I am still hoping Novartis jumps into this). Novo Nordisk took the lead from Lilly by making better tools for diabetic management. Novo Nordisk is by very far the biggest potential loser if and when Mannkind gets to sell their treatment. If Mannkind wins approval I will be looking at Novo Nordisk's share price to see how the market prices in Afrezza.
|
|
|
2014
Jan 1, 2014 19:51:42 GMT -5
Post by biotec on Jan 1, 2014 19:51:42 GMT -5
jpg
I agree with you, novo will not partner with mannkind. With that Sept interview with CFO Brandgaard I dont think we have to worry about A partnership with the worlds biggest diabetes play maker out there (Novo nordisk) Thats not a good thing!. This is not a good sign imo.Why does novo have the most to loss? Their the biggest beast out in the market today.This was the first article I've seen from a executive of a BP talk about Afrezza in an interview.I wish and hope that Novo is in the game for partnership. Remember this interview was in Sept 2013 after the new trials was out to the public. Well have to see what happens, Going to be a couple exciting months for Mannkind ahead. Im sure great news will follow with the Adam F Etc bad stuff. Im no way down playing MNKD, Im long been long since 2008. Just like to think what others have to say. Thanks
Bio
|
|
|
2014
Jan 1, 2014 22:14:57 GMT -5
Post by brentie on Jan 1, 2014 22:14:57 GMT -5
Yes brentie, Thanks. This is from the CFO of novo nordisk. This always buged me seeing novo is the king of insulin. Matt said way back in 2009 that novo would be a bad partner... Headline : Mannkind could be targeted down the road, CFO says Proprietary Intelligence Main body : Mannkind (NASDAQ:MNKD), the Valencia, California-based biotech company, is considered a target and eventually could be bought by a larger pharmaceutical company, said Matthew Pfeffer, CFO. Mannkind, with a market cap of USD 346.9m, is under no pressure to sell as it has enough cash to sustain itself into 2Q next year, said Pfeffer, citing a USD 350m line of credit the company secured. Mannkind is nearly 50% owned by CEO Alfred Mann, who has a track record of growing and selling companies, added Pfeffer. However, the company will have to grow much larger before it is sold, he said. When asked for a specific size, Pfeffer declined to comment, but said that Mann has invested over USD 1bn of his own money into the company. Mannkind recently submitted a new drug application for Afresa, a drug indicated for the treatment of type I and type II diabetes, and it hopes to receive a response from the FDA sometime early next year. The drug, an inhaled formulation of insulin, starts working in about 12 to 14 minutes, compared to current drugs which take nearly an hour to work, said Pfeffer. Additionally, Afresa is removed from the body quickly, which lowers the risk for hypoglycemia, a known problem for diabetics because of too much insulin in the system, he said. When asked how Afresa was different from Pfizer's failed Exubera, Pfeffer noted that Exubera's selling point was only that it was an inhaled insulin; it offered no extra benefit except its delivery method. Afresa is not only an inhaled formulation of insulin, but its real value is the compound works faster and could be safer than current treatment, he noted. Exubera was discontinued by Pfizer shortly after it was launched into the market. When asked if Pfizer could be interested in Afresa, Pfeffer said Pfizer is currently not in discussions with Mannkind about Afresa, although Pfizer recently sold its insulin manufacturing facility to Mannkind for USD 40m. Mannkind is currently in a number of partnership talks with large pharmaceutical companies and expects to enter a transaction, or partnership deal, before its cash runs out next year, said Pfeffer. In terms of possible partners, Pfeffer declined to comment but cautioned companies likely to be considered a good fit such as Denmark-based Novo Nordisk or Indianapolis, Indiana-based Eli Lilly may be poor choices, as Afresa could cannibalize their other diabetes products.
|
|
|
2014
Jan 2, 2014 21:12:03 GMT -5
Post by jpg on Jan 2, 2014 21:12:03 GMT -5
jpg I agree with you, novo will not partner with mannkind. With that Sept interview with CFO Brandgaard I dont think we have to worry about A partnership with the worlds biggest diabetes play maker out there (Novo nordisk) Thats not a good thing!. This is not a good sign imo.Why does novo have the most to loss? Their the biggest beast out in the market today.This was the first article I've seen from a executive of a BP talk about Afrezza in an interview.I wish and hope that Novo is in the game for partnership. Remember this interview was in Sept 2013 after the new trials was out to the public. Well have to see what happens, Going to be a couple exciting months for Mannkind ahead. Im sure great news will follow with the Adam F Etc bad stuff. Im no way down playing MNKD, Im long been long since 2008. Just like to think what others have to say. Thanks Bio Bio, That the CEO of Novo Nordisk says this is not, in my opinion, a good or bad thing. It is simply what he must say seeing he will have to compete against Mannkind's product in a fierce market. If the CEO of Novo Nordisk praised a computing product shareholders and the board would rightfully be puzzled... Affrezza will be taking market share out of every product line (pills and injectables) with the possible exception of Metformin. Novo Nordisk being a pure play in diabetic care would have the most to loss and would therefore not be a good choice for Mannkind unless they bought Mannkind (which seems highly unlikely as they would probably not be willing to pay 'fair value' as defined by Mannkind stakeholders).
|
|